Homoharringtonine promotes BCR‑ABL degradation through the p62‑mediated autophagy pathway

Li,Su; Bo,Zhilei; Jiang,Ying; Song,Xianmin; Wang,Chun; Tong,Yin

doi:10.3892/or.2019.7412

Homoharringtonine promotes BCR‑ABL degradation through the p62‑mediated autophagy pathway

Authors:
- Su Li
- Zhilei Bo
- Ying Jiang
- Xianmin Song
- Chun Wang
- Yin Tong
View Affiliations

Affiliations: Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China
Published online on: November 20, 2019 https://doi.org/10.3892/or.2019.7412
Pages: 113-120
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance to tyrosine kinase inhibitors (TKIs) is currently a clinical problem in patients with chronic myelogenous leukemia (CML). Homoharringtonine (HHT) is an approved treatment for adult patients with chronic‑ or accelerated‑phase CML who are resistant to TKIs and other therapies; however, the underlying mechanisms remain unclear. In the present study, HHT treatment demonstrated induction of apoptosis in imatinib‑resistant K562G cells by using MTS assay and western blotting, and BCR‑ABL protein was reduced. CHX chase assay revealed that HHT induced degradation of the BCR‑ABL protein, which could be reversed by autophagy lysosome inhibitors Baf‑A1 and CQ. Next, HHT treatment confirmed the induction of autophagy in K562G cells, and silencing the key autophagic proteins ATG5 and Beclin‑1 inhibited the degradation of the BCR‑ABL protein and cytotoxicity. In addition, autophagic receptor p62/SQSTM1(p62) participated during the autophagic degradation of BCR‑ABL induced by HHT, and this was confirmed by co‑immunoprecipitation, in which HHT enhanced the ubiquitination of the BCR‑ABL protein and promoted its binding to p62. In conclusion, HHT induced p62‑mediated autophagy in imatinib‑resistant CML K562G cells, thus promoting autophagic degradation of the BCR‑ABL protein and providing a novel strategy for the treatment of TKI‑resistant CML.

View Figures

View References

1	Shtivelman E, Lifshitz B, Gale RP and Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:550–554. 1985. View Article : Google Scholar : PubMed/NCBI
2	Druker BJ: Translation of the philadelphia chromosome into therapy for CML. Blood. 112:4808–4817. 2008. View Article : Google Scholar : PubMed/NCBI
3	Chopade P and Akard LP: Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 18:710–723. 2018. View Article : Google Scholar : PubMed/NCBI
4	Jabbour E, Kantarjian H and Cortes J: Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 15:323–334. 2015. View Article : Google Scholar : PubMed/NCBI
5	Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood. 99:3530–3539. 2002. View Article : Google Scholar : PubMed/NCBI
6	Larson RA: Is there a best TKI for chronic phase CML? Blood. 126:2370–2375. 2015. View Article : Google Scholar : PubMed/NCBI
7	Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B and Hallek M: The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem. 272:33260–33270. 1997. View Article : Google Scholar : PubMed/NCBI
8	Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D and Pear WS: BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood. 99:4122–4130. 2002. View Article : Google Scholar : PubMed/NCBI
9	Inoue A, Kobayashi CI, Shinohara H, Miyamoto K, Yamauchi N, Yuda J, Akao Y and Minami Y: Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. Int J Hematol. 108:365–370. 2018. View Article : Google Scholar : PubMed/NCBI
10	Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, Altman JK and Platanias LC: Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 120:3555–3562. 2012. View Article : Google Scholar : PubMed/NCBI
11	Valencia-Serna J, Aliabadi HM, Manfrin A, Mohseni M, Jiang X and Uludag H: SiRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo. Eur J Pharm Biopham. 130:66–70. 2018. View Article : Google Scholar
12	Davidson BL and McCray PB Jr: Current prospects for RNA interference-based therapies. Nat Rev Genet. 12:329–340. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kim DH and Rossi JJ: Strategies for silencing human disease using RNA interference. Nat Rev Genet. 8:173–184. 2007. View Article : Google Scholar : PubMed/NCBI
14	Shibata N, Shimokawa K, Nagai K, Ohoka N, Hattori T, Miyamoto N, Ujikawa O, Sameshima T, Nara H, Cho N and Naito M: Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase. Sci Rep. 8:135492018. View Article : Google Scholar : PubMed/NCBI
15	Lu S and Wang J: Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol. 7:22014. View Article : Google Scholar : PubMed/NCBI
16	Quintas-Cardama A and Cortes J: Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 14:4392–4399. 2008. View Article : Google Scholar : PubMed/NCBI
17	O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M and Talpaz M: Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 86:3322–3326. 1995. View Article : Google Scholar : PubMed/NCBI
18	Kantarjian HM, O'Brien S and Cortes J: Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval. Clin Lymphhoma Myeloma Leuk. 13:530–533. 2013. View Article : Google Scholar
19	Al Ustwani O, Griffiths EA, Wang ES and Wetzler M: Omacetaxine mepesuccinate in chronic myeloid leukemia. Exp Opin Pharmacother. 15:2397–2405. 2014. View Article : Google Scholar
20	Gurel G, Blaha G, Moore PB and Steitz TA: U2504 determines the species specificity of the A-site cleft antibiotics: The structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 389:146–156. 2009. View Article : Google Scholar : PubMed/NCBI
21	Huang MT: Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharm. 11:511–519. 1975.
22	Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, et al: Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol. 87:507–515. 2008. View Article : Google Scholar : PubMed/NCBI
23	Sun Q, Li S, Li J, Fu Q, Wang Z, Li B, Liu SS, Su Z, Song J and Lu D: Homoharringtonine regulates the alternative splicing of Bcl-x and caspase 9 through a protein phosphatase 1-dependent mechanism. BMC Complement Altern Med. 18:1642018. View Article : Google Scholar : PubMed/NCBI
24	Chen J, Mu Q, Li X, Yin X, Yu M, Jin J, Li C, Zhou Y, Zhou J, Suo S, et al: Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells. Oncotarget. 8:40318–40326. 2017.PubMed/NCBI
25	Chen R, Gandhi V and Plunkett W: A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 66:10959–10966. 2006. View Article : Google Scholar : PubMed/NCBI
26	Novotny L, Al-Tannak NF and Hunakova L: Protein synthesis inhibitors of natural origin for CML therapy: Semisynthetic homoharringtonine (Omacetaxine mepesuccinate). Neoplasma. 63:495–503. 2016. View Article : Google Scholar : PubMed/NCBI
27	Zaffagnini G, Savova A, Danieli A, Romanov J, Tremel S, Ebner M, Peterbauer T, Sztacho M, Trapannone R, Tarafder AK, et al: P62 filaments capture and present ubiquitinated cargos for autophagy. EMBO J. 37:e983082018. View Article : Google Scholar : PubMed/NCBI
28	Rossari F, Minutolo F and Orciuolo E: Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy. J Hematol Oncol. 11:842018. View Article : Google Scholar : PubMed/NCBI
29	Talati C and Pinilla-Ibarz J: Resistance in chronic myeloid leukemia: Definitions and novel therapeutic agents. Curr Opin Hematol. 25:154–161. 2018. View Article : Google Scholar : PubMed/NCBI
30	Dikic I: Proteasomal and autophagic degradation systems. Ann Rev Biochem. 86:193–224. 2017. View Article : Google Scholar : PubMed/NCBI
31	Kraft C, Peter M and Hofmann K: Selective autophagy: Ubiquitin-mediated recognition and beyond. Nat Cell Biol. 12:836–841. 2010. View Article : Google Scholar : PubMed/NCBI
32	Lamark T, Svenning S and Johansen T: Regulation of selective autophagy: The p62/SQSTM1 paradigm. Essays Biochem. 61:609–624. 2017. View Article : Google Scholar : PubMed/NCBI
33	Moscat J, Karin M and Diaz-Meco MT: P62 in Cancer: Signaling adaptor beyond autophagy. Cell. 167:606–609. 2016. View Article : Google Scholar : PubMed/NCBI
34	Kocaturk NM and Gozuacik D: Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. Front Cell Dev Biol. 6:1282018. View Article : Google Scholar : PubMed/NCBI